Gender and sexuality are inextricable from health, and doctors need to understand their patients’ identities to provide the best care possible, said BJ Rimel, LGBTQ+ Symposium co-chair, medical director of the Cedars-Sinai Cancer Clinical Trials Office, and associate professor of obstetrics and gynecology in the Division of Gynecologic Oncology at Cedars-Sinai Cancer.
“If a patient comes in for a complaint of a cough, and we don’t capture their sex and gender information—it may be not necessary, a cough is a cough—but maybe that cough is because they are socially smoking,” Rimel said to The Cancer Letter. “In the LGBTQ+ community, tobacco use is much higher, so we know that that’s an important place where we can strategize to help with screening and hopefully tobacco cessation programs. But if we don’t ask the right questions, we’re not targeting the interventions appropriately.”
In gynecologic oncology, for example, having a clear picture of a patient’s social context—and knowing who their caregivers are—can inform decisions related to fertility, Rimel said.
“In cancer care, we’re providing care to the patient who has it, but also to the caregivers, and providing them with resources,” Rimel said. “If we don’t know who those caregivers are, or we’re not willing to talk to them, we’ve really sold that patient a less good version of their care.”
Yet gathering information on patients’ gender and sexuality is complicated by a long history of shame, stigma, and discrimination directed towards LGBTQ+ people, Rimel said.
Sexuality cannot be disconnected from other parts of one’s identity and social status.
Zul Surani
“Hiding has been part of our culture for a really long time,” Rimel said. “Sex and gender are often taboo topics in lots of different cultural places. It has not always been very easy for us in the LGBTQ+ community to come out.”
This is gradually changing, but disparities in health data remain, Rimel said.
“In my lifetime, I’ve experienced a dramatic shift, from having to come out to people on a one-on-one basis and making sure they don’t tell anybody, to being able to be completely open in my personal and professional life,” Rimel said. “It’s really made a dramatic difference in my quality of life as a human and in my quality of care as a patient. I imagine others may feel the same, but without that data to help guide us, we’re kind of guessing.”
Gender and sexuality impact every part of cancer care, starting with screening.
“Cancer screening tends to be gendered. Look at all the guidelines—there’s male and female,” Surani said. “There will be a presentation on how we talk about cancer screening in an inclusive way with LGBTQ+ populations, so they’re better engaged and they have the power to be able to ask all the right questions with their providers.”
Rimel, who will deliver that presentation, and her colleague, Toby Datta, are using national survey data to investigate cancer screening among LGBTQ+ communities and the particular needs of sub-groups.
“Screening for HPV-related disease is primarily done via a pelvic exam, and that’s not easy for all of our folks,” Rimel said. “The type of screening that we’re doing is slowly evolving. We’re wondering if we can do more self-sampling and other kinds of tests that may be better for folks, especially those who are uncomfortable with exams for any reason—and then teaching providers to be more sensitive about how those exams happen and what people may think or feel about them.”
As part of the goal of making care more inclusive, the symposium will address specific initiatives aiming to increase representation of LGBTQ+ individuals in cancer data.
“There’s a movement out of California through the California Dialogue on Cancer that is working on expanding the data dictionary to include LGBTQ+ populations, so that they’re no longer invisible and we better understand the cancer burden,” Surani said.
Hiding has been part of our culture for a really long time. Sex and gender are often taboo topics in lots of different cultural places. It has not always been very easy for us in the LGBTQ+ community to come out.
BJ Rimel
Cedars-Sinai is developing a strategy to better represent sexual and gender minorities in its clinical trial data and medical records. Even if the healthcare system does have information on patients’ genders and sexualities, actually capturing that data and understanding the bigger picture presents a challenge, Rimel said.
“We’ve made a big push to get that data captured,” Rimel said. “Once we have it, we can start to understand what’s missing and what’s there. What are the things that surprise us? What are the things that don’t surprise us? From that data, hopefully we’ll be able to be a better service to our community.”
Recognizing the intersection of race, sexuality, and gender will also guide discussions at the symposium, Surani said.
“The other component of this is, how do we include LGBTQ+ communities of color? People who belong to multiple minority groups are further marginalized, and as a result, they may receive partial care, or we just don’t see the full picture of what is happening with them,” Surani said. “Sexuality cannot be disconnected from other parts of one’s identity and social status.”
Rimel said she hopes the conference will spark discussion and open new doors in research.
“In 10 years, I’ve really seen the ability to talk about this publicly. I’ve seen interest, I’ve seen people starting to gather data and write papers,” Rimel said. “People come up to me—no longer in hushed tones in the bathroom, saying, ‘I heard that you take care of lesbian patients, can I send you one?’ Now, people email me and they have banners with their own pronouns on them.
“Nothing is ever perfect, and there’s still enormous work to be done, but I think we’re at least on a much more hopeful road and in a much more open place than we were when I started out.”
Cancer care is at an inflection point. The traditional boundaries between academic and community oncology are dissolving, requiring a reimagined approach to patient care and clinical research. At City of Hope, we are implementing a national model that integrates breakthrough research with accessible, advanced treatment across diverse geographic regions.
Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases.
How are cancer centers in two rural states—Kansas and South Carolina—weathering the challenges of Trump-era belt-tightening and uncertainty? Their directors weigh in on The Cancer Letter Podcast.
Amid the flood zone of today’s Washington, the confirmation hearing for Jayanta (Jay) Bhattacharya’s nomination as director of NIH was remarkably calm.
Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States. Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...
A protein designed by Cedars-Sinai Cancer investigators can cross the protective blood-brain barrier safely and deliver therapy directly into cancerous tumor cells, a preclinical study shows.